These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND EZH2, ENX-1, 2146, ENSG00000106462, Q15910, MGC9169 AND Prognosis
95 results:

  • 1. Prognostic impact of DTA mutation and co-occurring mutations in patients with myelodysplastic syndrome.
    Wang M; Chen P; Li D; Zhao M
    Mol Biol Rep; 2024 Sep; 51(1):985. PubMed ID: 39278886
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Genetic hallmarks and clinical implications of chromothripsis in childhood T-cell acute lymphoblastic leukemia.
    Pastorczak A; Urbanska Z; Styka B; Miarka-Walczyk K; Sedek L; Wypyszczak K; Wakulinska A; Nowicka Z; Szczepański T; Stańczak M; Fendler W; Kowalczyk J; Młynarski W; Lejman M
    Leukemia; 2024 Nov; 38(11):2344-2354. PubMed ID: 39192035
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Influence of genetic co-mutation on chemotherapeutic outcome in NPM1-mutated and FLT3-ITD wild-type AML patients.
    Wu Q; Zhang Y; Yuan B; Huang Y; Jiang L; Liu F; Yan P; Cheng J; Long Z; Jiang X
    Cancer Med; 2024 Aug; 13(15):e70102. PubMed ID: 39126219
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Hypomethylating agents plus venetoclax compared with intensive induction chemotherapy regimens in molecularly defined secondary AML.
    Shimony S; Bewersdorf JP; Shallis RM; Liu Y; Schaefer EJ; Zeidan AM; Goldberg AD; Stein EM; Marcucci G; Lindsley RC; Chen EC; Ramos Perez J; Stein A; DeAngelo DJ; Neuberg DS; Stone RM; Ball B; Stahl M
    Leukemia; 2024 Apr; 38(4):762-768. PubMed ID: 38378841
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Clinical characteristics and prognosis of acute myeloid leukemia patients with Runt-related transcription factor 1 mutation: A single-center retrospective analysis.
    Wang LY; Li Y; Jiang Q; Jiang H; Wang Y; Xu LP; Zhang XH; Liu KY; Tang FF
    Hematol Oncol; 2024 Mar; 42(2):e3256. PubMed ID: 38367260
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. prognosis and risk factors for ASXL1 mutations in patients with newly diagnosed acute myeloid leukemia and myelodysplastic syndrome.
    Yang L; Wei X; Gong Y
    Cancer Med; 2024 Jan; 13(1):e6871. PubMed ID: 38146893
    [TBL] [Abstract] [Full Text] [Related]  

  • 7.
    Choi YJ; Min YK; Lee ST; Choi JR; Shin S
    Ann Lab Med; 2024 Jul; 44(4):335-342. PubMed ID: 38145892
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Epigenetic vulnerabilities of leukemia harboring inactivating ezh2 mutations.
    Alqazzaz MA; Luciani GM; Vu V; Machado RAC; Szewczyk MM; Adamson EC; Cheon S; Li F; Arrowsmith CH; Minden MD; Barsyte-Lovejoy D
    Exp Hematol; 2024 Feb; 130():104135. PubMed ID: 38072134
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Clonal hematopoiesis and its evolution of myeloproliferative neoplasms].
    Zhang L; Dong H
    Zhonghua Yi Xue Za Zhi; 2023 Dec; 103(45):3608-3614. PubMed ID: 38018059
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. [Characteristics of genetic variants in 134 patients with Acute myeloid leukemia].
    He M; Zhao X; Tian H; Zhang S; Zhao F; Zhang X; Wu T
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Oct; 40(10):1222-1227. PubMed ID: 37730221
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Subclones with variants of uncertain clinical significance might contribute to ineffective hemopoiesis and leukemia predisposition.
    Giudice V; Serio B; Errichiello S; Ferrara I; Galdiero A; Bertolini A; Visconti R; De Novellis D; Guariglia R; Luponio S; Morini D; Della Corte AM; Sessa AM; Verdesca F; Langella M; Izzo B; Selleri C
    Eur J Haematol; 2023 Nov; 111(5):729-741. PubMed ID: 37501402
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. [Analysis of epigenetic modification gene mutations among patients with acute myeloid leukemia].
    Wei J; Qiu H; Zhou H; Chen Z; Miao L; Wang Y; Zhao L; Cai Z
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2023 Apr; 40(4):435-441. PubMed ID: 36972938
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATL.
    Kurahashi Y; Watanabe T; Yamamoto Y; Ureshino H; Kamachi K; Yoshida-Sakai N; Fukuda-Kurahashi Y; Yamashita S; Hattori N; Nakamura H; Kawaguchi A; Ushijima T; Sueoka E; Kimura S
    Blood Adv; 2023 Apr; 7(8):1545-1559. PubMed ID: 36516085
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Hitting the brakes on accelerated and blast-phase myeloproliferative neoplasms: current and emerging concepts.
    Bewersdorf JP; Rampal RK
    Hematology Am Soc Hematol Educ Program; 2022 Dec; 2022(1):218-224. PubMed ID: 36485103
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia.
    Lackner D; Geissler K
    Wien Med Wochenschr; 2023 Feb; 173(1-2):27-33. PubMed ID: 36414855
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Valemetostat: First approval as a dual inhibitor of EZH1/2 to treat adult T-cell leukemia/lymphoma.
    Dou F; Tian Z; Yang X; Li J; Wang R; Gao J
    Drug Discov Ther; 2022 Dec; 16(6):297-299. PubMed ID: 36310058
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Allogeneic hematopoietic cell transplantation can overcome the adverse prognosis indicated by secondary-type mutations in de novo acute myeloid leukemia.
    Song GY; Kim T; Ahn SY; Jung SH; Kim M; Yang DH; Lee JJ; Choi SH; Kim MY; Jung CW; Jang JH; Kim HJ; Moon JH; Sohn SK; Won JH; Park SK; Kim SH; Zhang Z; Ahn JS; Kim HJ; Kim DDH
    Bone Marrow Transplant; 2022 Dec; 57(12):1810-1819. PubMed ID: 36151367
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. An open-label, single-arm phase 2 trial of valemetostat for relapsed or refractory adult T-cell leukemia/lymphoma.
    Izutsu K; Makita S; Nosaka K; Yoshimitsu M; Utsunomiya A; Kusumoto S; Morishima S; Tsukasaki K; Kawamata T; Ono T; Rai S; Katsuya H; Ishikawa J; Yamada H; Kato K; Tachibana M; Kakurai Y; Adachi N; Tobinai K; Yonekura K; Ishitsuka K
    Blood; 2023 Mar; 141(10):1159-1168. PubMed ID: 36150143
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. A novel immune-related epigenetic signature based on the transcriptome for predicting the prognosis and therapeutic response of patients with diffuse large B-cell lymphoma.
    Wang X; Hong Y; Meng S; Gong W; Ren T; Zhang T; Liu X; Li L; Qiu L; Qian Z; Zhou S; Zhao M; Zhai Q; Meng B; Ren X; Zhang H; Wang X
    Clin Immunol; 2022 Oct; 243():109105. PubMed ID: 36055572
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Clinical Significance of ezh2 in Acute Myeloid leukemia.
    Jiao W; Liu Y; Bao Y
    Comput Intell Neurosci; 2022; 2022():8741989. PubMed ID: 36052036
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.